Intellia Therapeutics (NASDAQ:NTLA) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.
NTLA has been the subject of a number of other reports. Barclays increased their price objective on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. JMP Securities began coverage on Intellia Therapeutics in a report on Thursday, March 8th. They issued an “outperform” rating for the company. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a report on Thursday, March 15th. Leerink Swann reissued an “outperform” rating on shares of Intellia Therapeutics in a report on Wednesday, March 14th. Finally, TheStreet raised Intellia Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 19th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $34.83.
Intellia Therapeutics opened at $27.39 on Friday, MarketBeat.com reports. The company has a market cap of $1.18 billion, a PE ratio of -14.57 and a beta of 3.21. Intellia Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.99.
In other Intellia Therapeutics news, insider John M. Leonard sold 8,400 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean Francois Formela sold 39,245 shares of the stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total value of $936,778.15. The disclosure for this sale can be found here. Insiders sold a total of 54,331 shares of company stock valued at $1,305,796 over the last three months. Corporate insiders own 12.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of NTLA. Schwab Charles Investment Management Inc. boosted its stake in Intellia Therapeutics by 37.6% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 79,129 shares of the company’s stock valued at $1,521,000 after purchasing an additional 21,637 shares in the last quarter. Swiss National Bank boosted its stake in Intellia Therapeutics by 91.8% during the 4th quarter. Swiss National Bank now owns 39,700 shares of the company’s stock valued at $763,000 after purchasing an additional 19,000 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in Intellia Therapeutics during the 4th quarter valued at $1,249,000. Wells Fargo & Company MN boosted its stake in Intellia Therapeutics by 108.0% during the 4th quarter. Wells Fargo & Company MN now owns 34,767 shares of the company’s stock valued at $668,000 after purchasing an additional 18,050 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in Intellia Therapeutics during the 4th quarter valued at $323,000. 60.74% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.